Inclusion Criteria: * Age 12 years and above * Mild or moderate bone marrow failure defined by satisfying specific conditions. * Diagnosis of telomere biology disorders Exclusion Criteria: * Women of child bearing potential or breastfeeding. * Patients with cancer who are on active chemotherapeutic treatment. * Patients with severe bone marrow failure. * Clonal cytogenetic abnormalities associated with MDS or AML on bone marrow examination. * Uncontrolled bacterial, viral or fungal infections. * Prior allogeneic marrow or stem cell transplantation. * Patients who are not eligible for G-CSF and plerixafor dosing. * Patients who are not eligible for the apheresis. * Patients currently taking or have taken danazol and androgens within 60 days prior to Day 1. * Patients with any other clinically relevant acute or chronic diseases which could interfere with the patients' safety during the trial, expose them to undue risk, or which could interfere with study objectives. * Patients who have participated in another clinical trial with an investigational drug within the previous 30 days.